BMS-986278

Generic Name: BMS-986278

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₁N_₅O_₅

CAS Number: 2170126-74-4

Unique Ingredient Identifier: 4UN9AOU6G8

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

Phase 1

Not yet recruiting

Conditions: Kidney Failure, Chronic
Healthy Volunteers
Renal Impairment

Interventions: Drug: BMS-986278

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06723535

Locations: 🇺🇸
Local Institution - 0003, Miami, Florida, United States
🇺🇸
Local Institution - 0002, Miami, Florida, United States
🇺🇸
Local Institution - 0004, Orlando, Florida, United States

and more 1 locations

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: BMS-986278

First Posted Date: 2024-05-22

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT06425198

Locations: 🇺🇸
Local Institution - 0001, Miami Lakes, Florida, United States
🇺🇸
Local Institution - 0003, Orlando, Florida, United States
🇺🇸
Elixia, Tampa, Florida, United States

and more 1 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Phase 3

Recruiting

Conditions: Progressive Pulmonary Fibrosis

Interventions: Drug: BMS-986278
Drug: BMS-986278 Placebo

First Posted Date: 2023-09-06

Last Posted Date: 2024-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1092

Registration Number: NCT06025578

Locations: 🇨🇦
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
🇫🇷
Local Institution - 0360, Rennes, France
🇫🇷
Hôpital Larrey, Toulouse, France

and more 525 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Phase 3

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BMS-986278 Placebo
Drug: BMS-986278

First Posted Date: 2023-08-22

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1185

Registration Number: NCT06003426

Locations: 🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸
Ocala Lung & Critical Care, Ocala, Florida, United States
🇩🇪
Krankenhaus der Augustinerinnen- Klinik fuer Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Cologne, Northwest, Germany

and more 496 locations

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Drospirenone/Ethinyl Estradiol
Drug: BMS-986278

First Posted Date: 2023-08-14

Last Posted Date: 2024-01-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT05985590

Locations: 🇨🇦
Local Institution - 0002, Québec, Quebec, Canada

A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Itraconazole
Drug: Gemfibrozil
Drug: Carbamazepine

First Posted Date: 2023-07-06

Last Posted Date: 2023-10-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 47

Registration Number: NCT05932303

Locations: 🇨🇦
Local Institution - 0001, Québec, CA, Canada

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986278
Drug: Placebo

First Posted Date: 2023-04-10

Last Posted Date: 2023-09-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT05805904

Locations: 🇨🇳
Local Institution - 0001, Shanghai, China

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2023-01-13

Last Posted Date: 2023-08-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT05684289

Locations: 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Phase 2

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: BMS-986278
Other: BMS-986278 Placebo

First Posted Date: 2020-03-16

Last Posted Date: 2023-10-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 399

Registration Number: NCT04308681

Locations: 🇨🇳
Local Institution - 0175, Taipei, Taiwan
🇦🇺
Local Institution - 0021, Murdoch, Western Australia, Australia
🇬🇧
Local Institution, London, United Kingdom

and more 101 locations

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis (IPF)

Interventions: Drug: BMS-986278
Drug: Pirfenidone

First Posted Date: 2019-06-10

Last Posted Date: 2020-05-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT03981094

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy